Packaging
Single-dose vials.
Equine Respiratory Disease Complex (ERDC) is caused by equine herpesvirus (rhinopneumonitis), influenza A equine-1 (H7N7), and influenza A equine-2 (H3N8). These viral infections can lead to severe inflammation and respiratory tract damage, significantly impacting performance, recovery, and overall health.
Approved for the treatment of ERDC of viral origin, Equimune® is a mycobacterium cell wall fraction (MCWF) immunostimulant that helps minimise lung damage, stimulate healing and accelerate recovery—making it an essential tool in respiratory disease management for performance and breeding horses.
How Equimune® works:
Stimulates immune response, enhancing antigen-presenting cells and boosting Interleukin-1 (IL-1) production.
Minimises lung damage, reducing inflammatory effects of viral infections.
Accelerates recovery, helping horses return to normal up to 85% faster than conventional treatments.
Studies show that a single IV dose generates a strong, non-specific immune amplification, allowing faster viral clearance and reduced severity of symptoms
Single-dose treatment via intravenous (IV) injection.
Optimal timing: Administer at the onset of clinical signs during the early acute phase for best immune response and faster recovery.
NovaVive Inc. is a Canadian company developing immune-enhancing alternatives to antibiotics using its proprietary MCWF technology—including treatments for equine endometritis and viral respiratory disease. Visit novavive.ca to learn more.
Equimune® contains a purified mycobacterium cell wall fraction (MCWF) that stimulates the horse's immune system. It activates antigen-presenting cells, enhancing the production of interleukin-1 (IL-1), a cytokine that amplifies both cell-mediated and humoral immune responses. This activation aids in combating viral infections and supports the healing of respiratory tract tissues.
Yes, Equimune® is safe for use in all horses, including pregnant mares. However, horses with a history of hypersensitivity reactions should be monitored closely. In rare cases, mild fever, drowsiness, or decreased appetite may occur for one to two days post-injection, which are normal responses to IL-1 release.
Yes, Equimune® is compatible with standard treatment and vaccination regimens. However, it should not be used concurrently with corticosteroids or ACTH, as these can reduce IL-1 production and diminish the immunostimulant effect.
Equimune® should be stored at 2°C to 7°C and should not be frozen. Once opened, the entire contents should be used immediately, and aseptic techniques should be observed during administration.
Yes, Equimune® should not be administered within 21 days of slaughter.